Member Info for Tiger16

If ImmuPharma (IMM) were to strike a licensing or buyout deal with a major pharmaceutical company for their late-stage asset P140, the financial upside could be very significant, but exact figures depend on several factors. Here’s a breakdown of what could realistically happen:

⸻

1. P140’s Value Potential

P140 (also known as Lupuzor™) is being developed for Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease with limited treatment options.

• The global lupus market is projected to reach $4–5 billion by 2030.

• If P140 proves effective with a unique mechanism of action and strong safety profile, it could capture a large share of this market (10–30% would not be unrealistic).

• A potential peak annual revenue of $500M–$1B+ is conceivable.

⸻

2. Valuation of IMM in a Licensing or Buyout Deal

Depending on the stage of development and terms of the deal:

a. Licensing Deal

• Upfront payment: $50M–$100M+

• Milestone payments: $200M–$500M+ (tied to regulatory approval, sales milestones)

• Royalties: 10–20% on net sales

b. Full Buyout

• If a large pharma company sees P140 as a high-potential blockbuster, a buyout could range from $500M to over $1B (depending on trial results and market opportunity).

• IMM’s current market cap is under £50M — meaning a buyout could potentially multiply the share price 10x–20x or more.

⸻

3. Share Price Impact

• Even a strong licensing deal could push the share price up 5x–10x from current levels, given the low market cap and historical under-valuation.

• A full acquisition would likely price in future revenue, instantly reflecting a large premium — perhaps 20p to 40p+ (compared to ~3p–5p range recently).

⸻

4. Factors That Could Influence the Outcome

• Strength of Phase 3 data

• Regulatory alignment (e.g., FDA or EMA fast-track)

• Competitive landscape

• Terms of exclusivity or co-development

• Investor sentiment and deal structure (lump sum vs. royalties)

⸻

Conclusion

If IMM successfully lands a deal with a big pharma for P140, especially a buyout, the share price could rise many multiples — possibly in the 5x–20x range, depending on deal terms. This would make IMM one of the highest-leverage biotech trades in the small-cap space.

Ilovesushi < I agree , I sold ou of my Ai stock to come back here , as one can see that the current market in real time should we get a deal is going to take the SP to very new highs , I personally feel there will be buy out ..

Many have posted a dis like the CEO and that he cannot be trusted , No one would commit career suicide by advising in clear ENGLISH , not one but two interviews that I quote " we are in talks with the big boys and all the want to see is the data .. hello ..

6 weeks passed now , one would imagine the deal done and dusted .. this coming week could be massive ..

Guys hope all are enjoying the bank holiday weekend

so we are now in the second Q , how long is this audit going to take now .. clearly from the sounds of things , and previous RNS to date , they need to recover the missing funds to complete the Audit , this is the delay here ..

Operational news good be a reversed take over or one Company Global and PPP become one ...

I guess as long as the CEO is still present we have a significant chance to come back and not be de listed ..

I just cant get my head around why the confirmation statement is still not complete ..

Mr jones Smith , now that is very interesting indeed Sir .. 113 per cent up yet news expect late May .. might be a idea to take a position here myself come Tues .. as i felt news would take some more time , as I for one have this firmly on my watch list ..

When do you expect news ?

Also any one sitting on the sidelines should always do their own research and look into the facts, and only invest if they feel it’s a good investment , your money your choice as we all know this is Aim and things do go wrong .. and one can loose their money , I have a few times on some speculative stocks over the years , yet I don’t see it as a loss now as I have learnt from my mistakes and now am able to read the markets and above all do my own research through asking those with more experience and knowledge, IM not afraid to ask and learn..

Good luck all .. and for the record my opinions are not financial advice . Just my opinions . And why I am invested and will now remain so until news lands .

IMM Update – Strong Momentum and Clear Potential Emerging

• Major Share Price Spike This Week: IMM’s share price surged by nearly 51% earlier this week, following the renewed attention on its late-stage asset P140, and has notably held those gains. This level of sustained interest is often seen when investors sense material developments are close.

• RNS – March 13th: The company released a significant RNS outlining the unique mechanism of action behind P140 — a first-in-class immunomodulator that acts at the root cause of autoimmune diseases by targeting dysfunctional autophagy in immune cells.

• Differentiation is Key: Unlike current treatments that often suppress the immune system broadly, P140 selectively resets immune balance. This gives it the potential for fewer side effects, broader indications, and possibly longer patent life — a very attractive proposition for large pharmaceutical companies.

• CEO Comments – Strategic Discussions Underway: IMM’s CEO has publicly stated that the company is in discussions with major pharmaceutical companies. This adds weight to the current momentum and suggests potential licensing, partnership, or acquisition interest could be active behind the scenes.

• Late-Stage Asset: P140 has already completed a Phase 2b trial in lupus (SLE) with statistically significant and clinically meaningful data. With a defined regulatory pathway, it represents a de-risked opportunity for partners to move straight into Phase 3 or registration trials.

• Massive Market Opportunity: The global lupus market alone is projected to exceed $3–4 billion annually. Given the mechanism could extend to other autoimmune diseases (e.g., Sjögren’s, Crohn’s, etc.), P140 could ultimately address a multi-billion-dollar franchise opportunity.

• Attractive Deal Potential: Comparable licensing deals or acquisitions in this space have reached hundreds of millions upfront with milestone payments exceeding $1 billion, especially for differentiated, late-stage autoimmune drugs. IMM’s current market cap is still modest in that context.

• Share Price Resilience: The fact that IMM has held its 50% gain post-spike suggests confidence in the underlying story — not just a news-driven trade. This kind of resilience is often seen when long-term holders and institutions start positioning.

• Why This Matters Now: With the RNS laying scientific groundwork, the CEO confirming pharma talks, and the market showing unusual strength in a tough biotech environment — everything points to news being imminent. While nothing is guaranteed, the risk/reward profile has shifted significantly.

⸻

Final Thought: This isn’t about hype — it’s about timing, potential, and positioning. IMM is now clearly on the radar, and further developments could re-rate it entirely if a formal partnership or deal is confirmed.

Hence guys yes I left the party for a few weeks as I felt news will take at least several we

Apologies .. Lord S F .. type error the word I was looking for was your talented and have a great sense of Humor , with I believe comes from experience of life ..

We will all do well here , allow me to explain why shortly ..

Your intergalactic.. allow me to gracefully express that if you have invested 5 k plus . Unwilling make some serious money .

God bless old chap

200 per cent agree cold girl .. I’m with you all the way .. . Let’s hope it comes this Tuesday.. god bless

Warrie we are all entitled to voice why we have sold or bought into this share , that is what the board is for .

I’m no longer invested hence won’t be posting on here now , until I might choose to buy in again if the AGM goes well and we have a clear picture that a alliance now can be formed .. then this is a great stock to be in , and one with a strong future ..

These are my opinions and we all must do our research and never allow anyone to influence our decisions to buy or sell and if they do on here , without factual posts , then they shouldnt be trading , investing at all ..

Good luck all ..

Steve E , you acting like a baby , it’s ok for you to post on IMM advising the share is going to tumble without any facts to back it up and you’re not even invested .

I was invested here and gave reasons for moving on and expressed everyone must there own research . I could be wrong . I go by facts not fiction like yourself .

You should be banned for being a bully and accusing those invested that they are not entitled to a voice that does not suit your criteria.. yet you can voice absolute rubbish on boards in stocks your not invested in .

Let’s see what happens here next week . I don’t see any alliance until the AGM has passed resolutions , in the mean time the sp will either stay stable or go slightly lower ..

By the way your filtered now .. absolute joker ..

Guys ignore the noise , where is cold girl ..

The fact is the have a late stage asset and are in talks with big pharmaceuticals , that is what the CEO has advised several times ..

The data is ground breaking and the recent spike in hours was for a reason ..

I expect to hear news early next week ..

This won’t be the first low cap stock / company to be bought out by a big pharmaceutical .. nor the last .

I’ve taken my position as it’s time now .. they have had 6 weeks to check data and tie up legal documents associated..

The reason I invested here and big was for one simple fact not fiction.

Melton is a billion dollar mining company .. that has the funds and resources to mine , prove , indicate , and can easily buy out a small cap like this in a punt .

Historical data confirm the asset and Melten are already next door , and about to list on the LSR as well as making an announcement that they will be investing Millions more in the critical minerals area ..

So 1 plus 1 equals 2 .. patients as When a deal comes this will go straight into suspension and we will be payed handsomely..

Eric Nat 16 what do you think is a target price here for a deal .. what could we expect per a share .

Even £1 seems cheap for a billion USD market . Yet the would probably sell for 50 p a share ..

Steve E , are you invested here , or are we just spreading FUD ?

Lord load so folly , anything can happen hear .. the asset is advanced and our CEO has advised talks with big fishes , billion dolor market .. very possible . recovery in actions now before close ..

We should recover before close . large spread here ..

Come drop a blinder and give us all the best bank holiday present .. we are waiting ..

Jungle VIP , many thanks for your support , yet I dont post on boards that I am not a active investor in .. whats the point .. good luck all ...

Steve e that was my last post on here , my apologies , I was just sharing , I could be wrong , who knows .. The alliance would certainly be a serious capital boast ..

good luck all ..

back to my medical dog ..